Online Shop
Abacavir
Aceclofenac
Acyclovir
Adefovir
Alfuzosin
Amiloride
Amlodipine
Amoxycillin
Anastrozole
Atropine
Azathioprine
Azithromycin
Baclofen
Bencyclane
Bicalutamide
Bisacodyl
Bisoprolol
Bosentas
Brimonidine
Butenafine
Calcitriol
Capecitabine
Cefixime
Cefoperazone
Cefotetan
Clindamycin
Clobetasone
Clonidine
Cyclosporine
Cyclosporine
Dacarbazine
Desonide
Dextroamphetamine
Didanosine
Duloxetine
Dutasteride
Efavirenz
Emtricitabine
Estradiol
Etoricoxib
Felodipine
Fenofibrate
Finasteride
Flucloxacillin
Fluvoxamine
Formoterol
Formoterol-Budesonide
Gliclazide
Goserelin
Hepatitis
Hyaluronate
Hydrocortisone
Hydroxyurea
Hypromellose
Indinavir
Insulin
Irinotecan
Isotretinoin
Itopride
Ketoconazole
Lamivudine
Levosalbutamol
Linezolid
Lisinopril
Lopinavir
Mercaptopurine
Mesalazine
Mometasone
Mycophenolate
Nateglinide
Nebivolol
Nelfinavir
Nevirapine
Nitrendipine
Olmesartan
Ondansetron
Ormeloxifene
Ornidazole
Orphenadrine
Oseltamivir
Oxcarbazepine
Oxybutynin
Oxytetracycline
Paracetamol
Paracetamol
Piroxicam
Progestin
Propranolol
Pyrantel
Quetiapine
Rabeprazole
Ranolazine
Risedronate
Rizatriptan
Rosiglitazone
Salbutamol
Saquinavir
Sildenafil
Sorbitol
Sucralfate
Tamsulosin
Telmisartan
Tenofovir
Tobramycin
Torsemide
Venlafaxine
Voriconazole
Warfarin
Zolmitriptan

Risedronate.

Structure

- 75 mg - Risedronate Sodium;

Without a Prescription

Risedronate 75 is prescribed for the treatment and prevention of osteoporosis in postmenopausal women.

Treatment of Osteoporosis
In postmenopausal women with osteoporosis, risedronate increases BMD and reduces the incidence of vertebral fractures and a composite endpoint of non-vertebral osteoporosis-related fractures.

Prevention of Osteoporosis
Risedronate 75 may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of fracture. Factors such as family history of osteoporosis, previous fracture, smoking, BMD (at least 1 SD below the pre-menopausal mean), high bone turnover, thin body frame, Caucasian or Asian race, and early menopause are associated with an increased risk of developing osteoporosis and fractures. The presence of these risk factors may be important when considering the use of risedronate for prevention of osteoporosis.

Dosage

Risedronate 75 should be taken at least 30 minutes before the first food or drink of the day other than water. To facilitate delivery to the stomach, Risedronate 75 should be swallowed while the patient is in an upright position and with a full glass of plain water (6 to 8 oz). Patients should not lie down for 30 minutes after taking the medication. Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate. Calcium supplements and calcium-, aluminum-, and magnesium-containing medications may interfere with the absorption of Risedronate 75 and should be taken at a different time of the day. Risedronate 75 is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min). No dosage adjustment is necessary in patients with a creatinine clearance >/=30 mL/min or in the elderly.

Treatment of Postmenopausal Osteoporosis
One 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month.

Prevention of Postmenopausal Osteoporosis
One 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month.

If both tablets are missed, take one Risedronate 75 mg tablet in the morning after the day it is remembered and then the other tablet on the next consecutive morning.
If one or both tablets of Risedronate 75 mg on two consecutive days/month are missed, and the next month`s scheduled doses are more than 7 days away, the patient should be instructed as follows:
If one or both tablets of Risedronate 75 mg on two consecutive days/month are missed, and the next month`s scheduled doses are within 7 days, patients should wait until their next month`s scheduled doses and then continue taking Risedronate 75 mg on two consecutive days/month as originally scheduled.
If only one Risedronate 75 mg tablet is missed, take the missed tablet in the morning after the day it is remembered.
Patients should then return to taking their Risedronate 75 mg on two consecutive days/ month as originally scheduled. Patients should not take more than two 75 mg tablets within 7 days.

Contraindications


- Known hypersensitivity to any component of this product;
- Inability to stand or sit upright for at least 30 minutes;
- Hypocalcaemia;

Form

Blister pack of 2 tablets.

Prescription drugs without a script
Prescription drugs no script
Prescription drugs no prescription
Prescription drugs without a prescription
RX no RX
RX without RX
2004 - 2017